Results 181 to 190 of about 55,546 (301)
A 60 Year Old Man with Activated Partial Thromboplastin Time without Hemorrhagic Tendency
Fumio Maruyama, Nobuhiko Emi
openalex +2 more sources
An injectable deep eutectic solvent‐based ionic gel is developed for rapid in situ gelation and broad‐spectrum hemostatic functionality. The material combines high mechanical strength, strong tissue adhesion, and antibacterial activity, demonstrating potential as an advanced biofunctional gel for emergency bleeding control and wound care.
Jia‐Yu Yang +13 more
wiley +1 more source
A prolonged activated partial thromboplastin time indicates poor short-term prognosis in patients with hepatic encephalopathy: insights from the MIMIC database. [PDF]
Zhan L +11 more
europepmc +1 more source
Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time. [PDF]
A. du P. Heyns +3 more
openalex +1 more source
This study presents heparin‐derived nanoparticles (HP‐NPs) as a novel precision medicine platform that combines therapeutic and delivery functions. HP‐NPs target drug‐resistant glioblastoma stem cells, reprogramming them into a drug‐sensitive phenotype and significantly reducing tumor progression.
Vadim Le Joncour +14 more
wiley +1 more source
Activated Partial Thromboplastin Time and Anti-IIa Monitoring in Argatroban Anticoagulation in COVID-19 Patients on Venovenous Extracorporeal Membrane Oxygenation. [PDF]
Burša F +10 more
europepmc +1 more source
By simply conjugating thrombin's active‐site inhibitor, dabigatran, with an exosite inhibitor, aptamer HD1, the resulting EXosite‐ACTive site (EXACT) inhibitors show two orders of magnitude higher potency and selectivity via synergistic binding, while maintaining the aptamer's antidote‐reversible trait, yielding a potential substitute for the animal ...
Haixiang Yu +11 more
wiley +1 more source

